Altimmune Inc (NASDAQ:ALT) price on current trading day, rose 15.26% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.23.
A look at the stock’s price movement, the close in the last trading session was $3.67, moving within a range at $3.6 and $4.47. The beta value (5-Year monthly) was 0.891. Turning to its 52-week performance, $11.16 and $3.55 were the 52-week high and 52-week low respectively. Overall, ALT moved -19.58% over the past month.
Altimmune Inc’s market cap currently stands at around $325.77 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests down to a -88.80% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 22.22M, representing a 111,022.20% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ALT is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend ALT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ALT’s current price about -18.36% and -27.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.05, while 7-day volatility ratio is 13.86% and 8.34% in the 30-day chart. Further, Altimmune Inc (ALT) has a beta value of 1.30, and an average true range (ATR) of 0.44. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $12 and high of $35. Looking at the price targets, the low is -183.69% off current price level while to achieve the yearly target high, price needs to move -727.42%. Nonetheless, investors will most likely welcome a -491.02% jump to $25 which is the analysts’ median price.
If we refocus on Altimmune Inc (NASDAQ:ALT), historical trading data shows that trading volumes averaged 2.71 over the past 10 days and 2.54 million over the past 3 months. The company’s latest data on shares outstanding shows there are 77.01 million shares.
The 1.04% of Altimmune Inc’s shares are in the hands of company insiders while institutional holders own 53.13% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 22.45 million on 2025-03-14, giving us a short ratio of 7.0. The data shows that as of 2025-03-14 short interest in Altimmune Inc (ALT) stood at 2938.9998 of shares outstanding, with shares short falling to 22.47 million registered in 2025-02-14. Current price change has pushed the stock -41.33% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALT stock continues to rise going into the next quarter.
